Charge Modification of Lysine Mitigates Amyloid-β Aggregation

Area of Science:

• Neuroscience
• Biochemistry
• Molecular Biology

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-β (Aβ) peptide aggregation into toxic structures.
• Aβ aggregate formation in the brain is central to AD pathophysiology, causing synaptic dysfunction and cognitive decline.
• Investigating physiological factors influencing Aβ aggregation in vitro can offer insights into in vivo AD pathology.

Purpose of the Study:

• To examine the impact of physiological free amino acids on amyloid-β (Aβ) aggregation dynamics.
• To specifically investigate the role of positively charged amino acids, such as lysine, in modulating Aβ aggregation.
• To explore the effect of neutralizing lysine's positive charge on Aβ aggregation.

Main Methods:

• Utilized in vitro assays to monitor Aβ aggregation kinetics.
• Employed chemical modification (methylation) to neutralize the charge of lysine.
• Compared Aβ aggregation in the presence of native and modified lysine.

Main Results:

• Positively charged amino acids, particularly lysine, were found to influence Aβ aggregation dynamics.
• Methylation of lysine to neutralize its charge significantly inhibited Aβ aggregation.
• These results demonstrate that the charge distribution of amino acids is a critical factor in modulating Aβ aggregation.

Conclusions:

• Amino acid charge plays a significant role in regulating amyloid-β (Aβ) aggregation.
• Findings suggest potential therapeutic strategies targeting amino acid interactions with Aβ.
• Further research into physiological modulators of Aβ aggregation is warranted for AD understanding.